Melanie Adams
Family · Yakima, WANPI 1518343904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 247 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.4% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $27.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$852
- Argenx US, Inc.$461
- Neurelis, Inc.$348
- Pfizer$343
- Teva Pharmaceuticals USA, Inc.$326
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,786100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $1,455 |
| AstraZeneca(2 entities) | 13 | $852 |
| Argenx US, Inc. | 10 | $461 |
| Neurelis, Inc. | 12 | $348 |
| Pfizer | 31 | $343 |
| Teva Pharmaceuticals USA, Inc. | 15 | $326 |
| Neurocrine Biosciences, Inc. | 3 | $275 |
| Novartis | 9 | $272 |
| E.r. Squibb & Sons, L.L.C. | 2 | $251 |
| Eisai Inc. | 7 | $246 |
| UCB, Inc. | 7 | $216 |
| Lilly USA, LLC | 8 | $172 |
| Neuronetics, Inc. | 3 | $159 |
| Acorda Therapeutics, Inc | 6 | $155 |
| SK Life Science, Inc. | 6 | $146 |
| Banner Life Sciences, LLC | 6 | $141 |
| Biogen | 3 | $136 |
| Sumitomo Pharma America, Inc. | 6 | $107 |
| EMD Serono, Inc. | 3 | $90 |
| Cala Health, Inc. | 2 | $75 |
| Amneal Pharmaceuticals LLC | 3 | $70 |
| Lundbeck LLC | 3 | $70 |
| Otsuka America Pharmaceutical, Inc. | 2 | $47 |
| Acadia Pharmaceuticals Inc | 2 | $45 |
| TG Therapeutics, Inc. | 2 | $44 |
| Bristol Myers Squibb | 2 | $39 |
| Amylyx Pharmaceuticals, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $37 |
| Merz Pharmaceuticals, LLC | 1 | $35 |
| Genentech USA, Inc. | 1 | $26 |
| Sunovion Pharmaceuticals Inc. | 2 | $26 |
| Jazz Pharmaceuticals Inc. | 1 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $22 |
| Novo Nordisk | 1 | $17 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,786 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 24 | $146,429 |
| IngrezzaValbenazine Tosylate | 12 | $101,323 |
| InbrijaLevodopa | 20 | $69,530 |
| Emgality PenGalcanezumab-Gnlm | 46 | $36,856 |
| Nurtec OdtRimegepant Sulfate | 22 | $34,987 |
| FarxigaDapagliflozin Propanediol | 21 | $21,534 |
| EliquisApixaban | 13 | $9,829 |
| Memantine Hcl | 181 | $5,561 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 11 | $5,221 |
| Gabapentin | 143 | $4,652 |
| Levetiracetam | 113 | $3,008 |
| Divalproex Sodium | 38 | $2,675 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 90 | $2,542 |
| Duloxetine Hcl | 71 | $2,502 |
| FingolimodFingolimod Hcl | 11 | $2,318 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $326 | $146,42924 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $275 | $101,32312 claims |
| Acorda Therapeutics, IncInbrija | $155 | $69,53020 claims |
| PfizerNurtec Odt, Eliquis | $343 | $44,81635 claims |
| AstraZenecaFarxiga | $852 | $21,53421 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $70 | $46440 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Yakima
- Sarah PerlmanYakima$12K
- Tesa LinstadYakima$8K
- Frances HullYakima$6K
- Sharla PetersonKenmore$192K
- Zelda SwainSpokane$83K
- Savannah MorganRenton$76K
- Kevan PettersonSeattle$56K
- Kelly McFeeSunnyside$42K
- Cheryl SomersSpokane$31K
- Hye-Jin GehringBellevue$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.